C
Cryosa
Health Tech & Medtech · Arden Hills, United States · Founded 2018
Medical device company developing novel treatments for obstructive sleep apnea MoreLess
Cryosa, Inc. is a clinical-stage company focused on developing innovative treatments for moderate to severe Obstructive Sleep Apnea (OSA). The company operates in the medical technology sector and targets patients suffering from OSA, a condition characterized by repeated interruptions in breathing during sleep. Cryosa's proprietary technology offers a minimally invasive, incisionless solution that leverages a controlled cooling process to reduce tissue and open airways, eliminating the need for masks, hoses, or implants. The business model revolves around clinical trials, regulatory approvals, and eventual commercialization of their treatment. Revenue generation is anticipated through the sale of their medical devices and associated therapies once they receive market approval. Cryosa has successfully raised $8.25 million in Series A-2 funding to further develop their breakthrough treatment. The company is currently enrolling participants in a U.S. pilot study, ARCTIC 3, to evaluate the safety and effectiveness of their therapy.
Keywords: Obstructive Sleep Apnea, minimally invasive, incisionless, controlled cooling, clinical-stage, medical technology, OSA treatment, pilot study, Series A funding, airway management.
Company overview
Cryosa company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Arden Hills, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 66.3
Valuation & funding
Cryosa funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2021 | $22M | $86M | Sante Ventures · HOYA CORPORATION · Solas BioVentures | — |
| SERIES A✓Equity / VC | Jun 2020 | $8.3M | $33M | HOYA CORPORATION · Sante Ventures | — |
| SERIES A✓Equity / VC | May 2018 | $0 | — | Sante Ventures | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 14 |
| 2025 | 16 |
| 2024 | 25 |
| 2023 | 29 |
| 2022 | 26 |
| 2021 | 18 |
Growth signals
Cryosa website traffic
Latest recorded traffic for Cryosa is 1.8K monthly website visits, up 0% over the last three months. Cryosa's team declined 18.8% over the past year.
Comparisons
Cryosa compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Cryosa's talent
Source: Dealroom Talent Intelligence.
Investors
5 investors on Cryosa's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Cryosa has talent and traffic
team presence
In the news
Latest news about Cryosa
Recent press, funding announcements, and product moves mentioning Cryosa — open to read from the original sources.
Market sentiment
What the market is saying about Cryosa
An AI-synthesized read of the highest-engagement posts about Cryosa on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cryosa’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.